Next-generation companion diagnostics: Promises, challenges, and solutions

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 1, 2015, Pages 11-13

  Khoury, Joseph D ^a   Catenacci, Daniel V T ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LABORATORY TEST; METABOLISM; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PRACTICE GUIDELINE; PROCEDURES; PROTEOMICS; STANDARDS; TRENDS;

BIOMARKERS, TUMOR; CLINICAL LABORATORY TECHNIQUES; DNA MUTATIONAL ANALYSIS; GUIDELINES AS TOPIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEOMICS;

EID: 84920565542     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0063-ED     Document Type: Editorial

References (7)

1. Parkinson DR, Johnson BE, Sledge GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res. 2012;18(3):619-624.
2. Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med. 2013;369(25):2369-2371.
3. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023-1034.
4. US Food and Drug Administration. Guidance for industry and Food and Drug Administration staff: in vitro companion diagnostic devices. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm262292.htm. Accessed November 25, 2013.
5. Kurzrock R, Kantarjian H, Stewart DJ. A cancer trial scandal and its regulatory backlash. Nat Biotechnol. 2014;32(1):27-31.
6. College of American Pathologists. Proposed approach to oversight of laboratory developed tests. http://www.cap.org/apps/docs/advocacy/ldt/oversight-model.pdf. Accessed December 3, 2013.
7. Catenacci D, Polite B, Henderson L. Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity-PANGEA. J Clin Oncol. 2014;32(suppl 3):Abstract 66.